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engineering and regenerative medicine 
are considered as a potential solution to 
overcome this problem. Considerable 
advancements over the course of almost 
30 years resulted in therapeutic applica-
tions with successes for thin or avascular 
tissues and organs such as skin,[1] carti-
lage,[2] and bladder.[3] For biologically com-
plex tissue analogues and for upscaling 
of constructs to clinically relevant size, a 
major bottleneck for advancement to the 
clinical setting lies in the lack of vasculari-
zation.[4] Furthermore, there is a need for 
clinically relevant, degradable biomaterials 
that stimulate cell differentiation, matrix 
secretion and ultimately, functional tissue 
development.[5]
Hydrogels play an important role in 
tissue engineering approaches, since their 
3D polymer network, characterized by a 
high water content, can closely resemble 
the native extracellular matrix in the 
(developing) tissues. In fundamental stem cell culture, the most 
commonly used biomaterial is isolated from a mouse tumor 
(Engelbreth–Holm–Swarm), which is rich in extracellular 
matrix proteins with the trade name Matrigel (or Cultrex).[6] 
For creating functional tissue analogues in tissue engineering, stem cells 
require very specific 3D microenvironments to thrive and mature. Demanding 
(stem) cell types that are used nowadays can find such an environment in a 
heterogeneous protein mixture with the trade name Matrigel. Several vari-
ations of synthetic hydrogel platforms composed of poly(ethylene glycol) 
(PEG), which are spiked with peptides, have been recently developed and 
shown equivalence to Matrigel for stem cell differentiation. Here a clinically 
relevant hydrogel platform, based on PEG and gelatin, which even outper-
forms Matrigel when targeting 3D prevascularized bone and liver organoid 
tissue engineering models is presented. The hybrid hydrogel with natural 
and synthetic components stimulates efficient cell differentiation, superior to 
Matrigel models. Furthermore, the strength of this hydrogel lies in the option 
to covalently incorporate unmodified proteins. These results demonstrate how 
a hybrid hydrogel platform with intermediate biological complexity, when com-
pared to existing biological materials and synthetic PEG-peptide approaches, 
can efficiently support tissue development from human primary cells.
Gelatin-PEG
1. Introduction
Shortcomings of autologous tissue transplants and the shortage 
of donor organs are a major clinical burden to society. Tissue 
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The composition of Matrigel is heterogeneous with more than 
1500 different proteins in its makeup, with the most prevalent 
proteins being laminin, collagen type IV, and entactin.[7] This 
material is especially required for biologically demanding cell 
cultures, such as organoids[5,8] and vasculogenesis assays.[9] Its 
unique biological composition attributes its value for cell cul-
ture to the derivation from the basement membrane and allows 
cells to proliferate and differentiate. The basement membrane 
forms a specialized extracellular habitat of multiple organ and 
tissue systems throughout the body, making it an interesting 
target matrix for recapitulation.
Furthermore, even though Matrigel might appear as an ideal 
biomaterial from a biological perspective, there are numerous 
disadvantages that render it unsuitable for clinical applica-
tion.[10] High variability in composition and also stiffness, 
limits the batch reproducibility massively,[11] with a lot-to-lot 
similarity of only 53%.[7] The murine origin of Matrigel will 
furthermore complicate clinical translation due to immuno-
genic effects.[12]
To advance the translation of human tissue analogues to the 
clinics, new matrices with biological equivalence to the base-
ment membranes are of high relevance. Recent approaches 
to create these were based on completely defined synthetic 
hydrogel platforms, coupled with biological components in 
the form of peptides improving cell adhesion such as RGDs 
(arginylglycylaspartic acid).[13] In this study, laminins were 
chosen for incorporation because these represent the major 
protein present in Matrigel. Synthetic polymers are advanta-
geous since they are biologically inert and they have highly 
defined material and mechanical properties. To impart bio-
logical characteristics, inert synthetic polymers such as 
poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly-N-
isopropylacrylamide (PNIPAAM) require addition of bioactive 
peptide sequences. For example, in a vascular toxicity screen, a 
2D platform based on poly(ethylene glycol) (PEG) and peptides 
mimicking the functional groups of large ECM molecules 
(RGDs) outperformed Matrigel in terms of reproducibility and 
sensitivity.[13b] The screening assay typically involves cell cul-
ture periods for up to 24 h. Also, for stem cell expansion, the 
tailored PEG-based system with peptides maintained human 
embryonic stem cell pluripotency during the initial 4 d.[13b] 
Further, another group presented an elegant approach to 
expand and differentiate intestinal stem cells and organoids 
in a mechanically dynamic PEG-peptide-based hydrogel to 
foster fibronectin-based adhesion peptides and compared it to 
Matrigel.[13a] During culture over 4 d, intestinal stem cells sur-
vived and proliferated in the PEG-peptide hydrogels. Another 
variant of PEG hydrogels, spiked with RGDs and protease-
degradable peptides even allowed for 14 d cell differentiation 
protocols, which resulted in comparable levels of differentia-
tion as cultures in Matrigel.[13c]
These recent hydrogel developments are great achieve-
ments toward finding a clinically relevant replacement for 
Matrigel by showing biological equivalence. The next step lies 
in the further development of a tissue-specific tailorable mate-
rial, which allows for enhanced cell differentiation compared 
to Matrigel in order to more closely mimic the function of 
a native tissue. However, due to the low number of biologi-
cally active sites in synthetic matrices with spiked peptides, 
they have a reduced cell-driven remodeling capacity when 
compared to natural materials. Stimulating remodeling of 
the engineered matrix into a mature biologically functional 
tissue analogue implies successful long-term performance of 
encapsulated cells.[8] The native extracellular matrix (ECM) is 
a dynamic material, which provides residing cells with specific 
physical and chemical cues via binding sites.[14] The ECM is 
ascribed a crucial role in regulating the development, func-
tion, and homeostasis of residing cells.[15] Hence, an ideal 
scaffold material for engineering of tissues outside the human 
body will be one that mimics the natural architecture of the 
targeted tissue, which remains a significant challenge with the 
current technology.[14,16]
To bridge the gap between minimalistic approaches of 
synthetic, defined matrices, and biological materials, novel 
hydrogels that provide a matrix with intermediate biological 
complexity are needed for tissue engineering purposes. Gel-
atin can serve this purpose, as it is derived from the most 
abundant protein in the human body, collagen type I, which 
is highly conserved among species. It is associated with less 
immunogenicity than collagen while retaining bioactive sig-
nals of its native progenitor. Furthermore, gelatin is used, 
despite its animal origin, routinely in the clinics since several 
decades.[17]
In this study, we developed a gelPEG hydrogel platform 
aimed at recapitulating the biological functionality of the base-
ment membranes, while maintaining the simplicity, tailor-
ability, and reproducibility of synthetic hydrogels. This hybrid 
semisynthetic gelPEG platform uniquely combines its inherent 
support of cell performance, tailorability of physicochemical 
characteristics and highly versatile application by incorpora-
tion of natural (unmodified) tissue-specific proteins. A system-
atic material characterization is presented and tailored toward 
physicochemical parameters favoring multitissue differentia-
tion. The biological performance of the novel hydrogel is com-
pared to that of Matrigel. Vasculogenesis, a hallmark process 
for tissue engineering, is evaluated in gelPEG hydrogels and 
assessed regarding extent and maturity of the developed vas-
cular network in 3D. To demonstrate the enhanced cell-instruc-
tive capacity of the new basement membrane-inspired material, 
it was applied in engineering of prevascularized bone and liver-
like tissue analogues.
2. Results
2.1. Systematic Evaluation of gelPEG Hybrid Hydrogels
Hydrogels were fabricated by forming covalent crosslinks 
between gelatin and PEG via an enzymatic reaction with coag-
ulation factor XIII (FXIIIa). To do so, the specific amino acid 
substrate sequence (NQEQVSPL) of the enzyme was conju-
gated to 8 arm PEG (PEG-Gln), which can be crosslinked with 
the native lysine residues on gelatin (Figure 1). Moreover, in 
the same reaction step, other lysine-containing proteins may be 
coupled into the gelPEG hydrogel network to create a tissue-
specific ECM-like environment. Before crosslinking, cells were 
resuspended in the gelatin-PEG solution to form a 3D polymer 
network around the cells.
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The optimal crosslinking conditions between gelatin and PEG 
were established by mixing the two components in molar ratios 
between 1:1 and 6:1 (gelatin)Lys/(PEG)Gln at a constant overall 
polymer concentration of 3% w/v (Figure 2). Hydrogels with the 
lowest swelling ratio, indicating efficient crosslinking and there-
fore the best fabrication window, was from 1:1 to 4:1 gelatin/
PEG combination (Figure 2a). Since gelatin can be degraded 
and remodeled by cells, 4:1 gelatin/PEG was preferred over 2:1 
and 1:1 and chosen to proceed within further experiments. The 
swelling ratio decreased with increasing polymer concentration 
(Figure 2b). A polymer concentration of 1% w/v gelPEG resulted 
in mechanically unstable hydrogels that could not be manipu-
lated without destruction. The compressive moduli were 2.6 kPa 
± 0.6 for 2% and 6.8 kPa ± 2 for 3% w/v gelPEG hydrogels with 
significant differences (p = 0.0026) (Figure 2C). Rheological 
measurements indicated for 2% gelPEG at 4:1 molar ratio a 
point of gelation after 2 ± 1.5 min and the hydrogel was com-
pletely crosslinked after about 15 min (Figure S1, Supporting 
Information). Furthermore, coupling of lysine-containing pro-
teins of interest into the gelPEG network was demonstrated. 
To do so, laminin (LN) 521 was successfully incorporated in 
gelPEG hydrogels as indicated by anti-α5-LN staining in whole 
mount constructs (Figure S2b, Supporting Information).
2.2. Vasculogenesis in gelPEG Hydrogels Compared to Matrigel
The biological functionality of the novel developed gelPEG 
hydrogel for 3D vasculogenesis was assessed and compared to 
Matrigel, the gold standard for vasculogenesis. Low polymer 
content or crosslink densities resulting in soft hydrogels are 
needed to allow for cell migration[18] and enabling capillary 
network formation.[19] For this reason, we chose for this appli-
cation the 2% w/v gelPEG hydrogel formulation, which is rela-
tively stable (compared to 1%) and still relatively soft.
Interconnected endothelial cell networks from healthy 
human endothelial colony forming cells (ECFCs) were observed 
in Matrigel after 3 d, whereas similar capillary-like network took 
longer to be formed in gelPEG hydrogels and was observed 
after 6 d (Figure S3, Supporting Information). After a 10 d 
coculture of healthy human ECFCs and MSCs, highly inter-
connected vascular-like structures were present throughout all 
hydrogels (N = 3 donor combinations, Figure 3a,e; Figure S3c,f, 
Supporting Information). Quantification of total vessel length 
and average vessel thickness of 150 µm z-projections revealed 
comparable network formation in gelPEG and in Matrigel 
(Figure 3j,k). Also, in both matrices, vascular networks were 
stabilized by pericyte-like cells as indicated by αSMA staining 
Adv. Healthcare Mater. 2019, 8, 1900979
Figure 1. Enzymatic crosslinking reaction between PEG and gelatin. The FXIIIa-specific amino acid sequence for glutamine (gln), NQEQVSPL, was 
conjugated to 8 arm PEG (PEG-Gln), which can be crosslinked with lysine (lys) residues that are naturally occurring on gelatin. The reaction takes place 
under physiological conditions and cells can be encapsulated in the same step. It is also possible to immobilize other lysine-containing proteins in the 
hydrogel network for enhanced tissue specificity (see Figure S2, Supporting Information).
Figure 2. Physical fine-tuning and characterization of gelPEG hydrogels. a) Hydrogels with the lowest swelling ratio were obtained at a molar ratio 
(gelatin)Lys/(PEG)Gln of 2:1 for 3% w/v gelPEG. b) Decreasing gelPEG concentration resulted in higher swelling ratios. c) Compressive moduli were 
significantly increased from 2% to 3% gelPEG. n.d., not determined; lys: lysine; gln: glutamine; data are depicted as mean + SD; n = 5.
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(Figure 3b,f). Moreover, staining of VE-cadherin junctions in 
the capillary-like structures highlighted the cell–cell contacts 
of single endothelial cells, which had fused and remodeled 
into a further matured vessel (Figure 3c,g) containing lumen 
(Figure 3d,h). A close-up of the capillaries, showed filopodial 
extensions indicating active angiogenesis at various sites in the 
hydrogels (here in gelPEG hydrogel) (Figure 3i).
2.3. Development of Prevascularized Bone-Like  
Tissue Analogues
To further demonstrate the versatility and performance of 
the novel gelPEG hydrogels, prevascularized bone-like tissue 
analogues were cultured with human MSCs and ECFCs in 
the novel material and compared to Matrigel. Prevascular-
ized tissues can be engineered by using endothelial cells that 
self-assemble into vascular-like networks.[20] Furthermore, in 
a vascularized bone engineering approach, MSCs play a dual 
role. First, a part of these multipotent cells will differentiate 
into pericyte-like cells, which are needed for stabilization and 
maturation of capillary networks. Second, another fraction of 
MSCs will undergo osteogenesis toward the formation of bone 
tissue.[19c,21]
To increase gelPEG’s biological resemblance to Matrigel, 
one of its major components, laminin 111 (LN111),[6b] was 
immobilized in the gelPEG networks and taken along in the 
comparison. After a culture period of 2 weeks under osteo-
genic conditions, ECFC-MSC cocultures were analyzed for 
markers indicating prevascularization and osteogenesis. From 
a macroscopic point of view, gelPEG hydrogels became opaque 
during the culture period, whereas Matrigel remained rather 
transparent (Figure 4). Matrigel cultures were negative for von 
Kossa staining, while interestingly, all gelPEG hydrogels were 
mineralized (Figure 4a,e). Also, gelPEG hydrogels with LN111 
showed mineralization in seven out of nine constructs, which 
appeared more homogeneously distributed throughout the 
hydrogel when compared to pure gelPEG hydrogels (Figure 4i). 
The majority of cells in cocultures of all hydrogels were posi-
tive for the osteogenic marker osteonectin (Figure 4b,f,j). 
Late osteogenesis-related genes encoding for osteocalcin and 
osteopontin were expressed comparably in all hydrogel sys-
tems (Figure 4n,o). Moreover, vasculogenesis was present in 
all hydrogel compositions as shown in projections of 100 µm 
in the z-direction (Figure 4c,g,k). The total length of the cap-
illary-like network was comparable between Matrigel and 
gelPEG+LN111, whereas gelPEG hydrogels had a significantly 
shorter vascular-like network (Figure 4m). The gene expression 
Adv. Healthcare Mater. 2019, 8, 1900979
Figure 3. Vasculogenesis in gelPEG and Matrigel characterized by stabilized capillary-like structures with lumen. Human GFP-ECFCs and MSCs were 
cocultured for 10 d in EGM-2. a,e) Projections of 150 µm confocal stacks through a hydrogel. b,f) Stabilization of vascular networks by pericyte-like 
cells (red). c,g) Capillary-like structures were composed of multiple fused endothelial cells indicated by cell–cell contact by VE-cadherin junctions. 
d,h) Capillary-like structures in gelPEG and Matrigel were characterized by lumenization (dotted lines indicate cutting sections). i) Capillary-like struc-
tures with filopodia at a site of active angiogenesis, here in a gelPEG hydrogel. j,k) Total vessel length and average vessel thickness in gelPEG hydrogels 
and Matrigel. Data are depicted as mean + SD; N = 3, n = 3.
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Figure 4. Development of prevascularized bone-like tissue analogues in Matrigel and gelPEG-based hydrogels. ECFC-MSC cocultures were cultured 
for 2 weeks under osteogenic culture conditions in the different hydrogels before analysis of osteogenesis, vasculogenesis, and presence of pericyte-
like cells. Expression of BGLAP and SPP1 as osteogenic markers, CDH5 and PECAM1 were measured as endothelial markers and CSPG4 and ACTA2 
as pericyte markers. a,e,i) Von Kossa staining was positive for gelPEG and gelPEG+LN111 hydrogels highlighting mineralization. b,f,j) Sections of 
hydrogels highlighted the presence of the osteogenic marker osteonectin in all groups. c,g,k) 100 µm z-projections of vascular-like networks (green) 
in the centre of the hydrogels. d,h,l) Vascular-like structures, stabilized by αSMA-positive pericyte-like cells (red). m) Total vessel length was equal in 
Matrigel and gelPEG+LN111, and significantly longer than in gelPEG hydrogels. n,o) mRNA expression for osteogenic genes encoding for osteocalcin 
and osteopontin were comparably expressed in Matrigel, gelPEG, and gelPEG+LN111. p,q) Vasculogenesis-associated genes encoding for CD31 and 
VE-cadherin were expressed in all hydrogels, with highest VE-cadherin expression in Matrigel, followed by gelPEG and gelPEG+LN111. r,s) Pericyte-
associated genes encoding for αSMA and NG2 were equally expressed in all hydrogels. Data are depicted as mean + SD; N = 3, n = 3.
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levels encoding for CD31 were comparable between all condi-
tions (Figure 3n). However, the gene expression for VE-cad-
herin was significantly lower in gelPEG and gelPEG+LN111 
compared to Matrigel (Figure 4q). The capillary-like net-
works were supported by αSMA positive pericyte-like cells 
(Figure 4d,h,l) and pericyte-related genes encoding for αSMA 
and NG2 had comparable expression levels in all hydrogel com-
positions (Figure 4r,s).
Notably, Matrigel constructs lost thickness when compared 
to gelPEG-based constructs as also apparent in paraffin cross-
sections of the constructs (Figure 4a,b,e,f,i,j). At the same time, 
the diameter of all of the constructs stayed approximately the 
same (Figure 4, first column).
2.4. Development of Liver-Like Tissue Analogues
To further assess the biological performance of gelPEG hydro-
gels for biologically demanding cell cultures, liver organoids 
were encapsulated in tailored hydrogels and compared to a 
conventional culture protocol in Matrigel. Since the Matrigel 
used for this application, typically has a high protein concen-
tration and thus, higher stiffness, in analogy, also gelPEG was 
used at 3% w/v, to achieve stiffer hydrogels. These hydrogels 
were further supplemented with LN111, to better resemble 
Matrigel’s composition, or with LN521, since this LN is associ-
ated with improved hepatocyte performance.[22]
Hematoxylin and eosin (H&E) staining of liver organoids in 
the different matrices highlighted cell structures with similar 
morphology. However, in gelPEG-based hydrogels, the cell 
nuclei were located more toward the luminal side of the orga-
noid structures (Figure 5a–d).
Functional readout of the liver-like tissue analogues was per-
formed to investigate the quality of the engineered tissue. In 
terms of albumin production, liver organoids in gelPEG with 
added laminins performed best, with levels about 2–3 times 
higher than in Matrigel (Figure 5e). The liver-like tissues in 
gelPEG produced significantly higher enzyme levels of alanine 
aminotransferase (ALAT) and aspartate transaminase (ASAT) 
compared to Matrigel (Figure 5f,g). Lactate dehydrogenase 
Adv. Healthcare Mater. 2019, 8, 1900979
Figure 5. Development of liver-like tissue analogues in Matrigel (MG) and gelPEG-based hydrogels. A functional read-out of protein levels and 
enzyme activities was performed after 9 d culture of liver organoids. H&E staining of liver organoids in a) Matrigel, b) gelPEG, c) gelPEG+LN111, and 
d) gelPEG+LN521. e) Albumin protein levels in cultured organoid cell lysates. f,g) ALAT an ASAT enzyme activities of liver organoid cell lysates. h,i) 
LDH and GLDH enzyme levels of liver organoid cell lysates. Data are depicted as mean + SD; N = 3, n = 3.
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1900979 (7 of 13) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
(LDH) and the more liver-specific glutamate dehydroge-
nase (GLDH) indicate metabolic activity of hepatocytes in 
the different hydrogels. The same trend as observed for the 
enzyme levels of ALAT and ASAT could be seen for LDH and 
GLDH. Again, in Matrigel the levels were lowest compared 
to gelPEG-based hydrogels (Figure 5h,i). Overall, addition of 
LN111 or LN521 resulted in intermediate enzyme levels, being 
higher than in Matrigel (Figure 5). Compared to pure gelPEG 
hydrogels, overall, the addition of LN111 did not further 
enhance the enzyme levels, whereas LN521 had a slightly nega-
tive effect.
The metabolic activity as assessed by Alamar Blue (resazurin 
to resorufin) conversion by hepatocytes was monitored over cul-
ture time showing a steep increase from day 1 to day 3. After 
a culture period of 9 d, the activity was increased by 50% in 
Matrigel and gelPEG hydrogels, whereas in LN111 and LN521 
containing hydrogels, the activity was doubled when compared 
to day 1 (Figure S4, Supporting Information).
Furthermore, gene expression levels were quantified on day 
9. In contrast to the outcomes on protein level, albumin expres-
sion levels were highest in Matrigel and gelPEG and lower in 
gelPEG when LNs were added (Figure S5b, Supporting Infor-
mation). KRT7 (CK7), a cytokeratin that is specifically expressed 
in simple epithelia and can be used to detect bile ducts in the 
liver,[23] was equally expressed in all hydrogels (Figure S5a, 
Supporting Information). The cytochrome family of enzymes 
CYP2B6, CYP2C19, and CYP3A4, involved in drug metabo-
lism, e.g., showed comparable expression levels in Matrigel and 
gelPEG, whereas with the addition of laminins overall lower 
expression levels were detected (Figure S5d–f, Supporting 
Information). SLC10A1, which is encoding for a liver-specific 
sodium/bile acid cotransporter, was comparably expressed in 
all hydrogels (Figure S5c, Supporting Information).
3. Discussion
In this study, we present a novel, hybrid hydrogel of gelatin and 
PEG that is easily customized with (native) lysine-containing 
proteins. The presented tailored hydrogel platform performed 
as good as Matrigel in terms of 3D vasculogenesis and even 
outperformed Matrigel when employed for engineering of 
prevascularized bone- or liver-like tissue analogues.
3.1. Crosslinking of Gelatin and PEG by FXIIIa
The crosslinking strategy that was chosen in this study was 
compared to a Matrigel control. The main reason for this was 
that a direct comparison of the biosynthetic gelPEG platform 
to pure crosslinked gelatins, such as via microbial transglu-
taminase or UV crosslinked gelatin methacryloyl (gelMA), is 
inappropriate. The significant differences in the gelatin concen-
tration, hydrogel stiffness, and/or crosslinking density between 
these systems also affects cell behavior in these materials.
The composition of the herein presented hydrogel-plat-
form is based on a transglutaminase-catalyzed crosslinking 
mechanism (factor XIIIa), which was adopted from the blood 
coagulation cascade. The elegant strategy to make use of 
the recognition sequences of this enzyme for immobilizing 
instructive peptides in hydrogels was developed by Hubbell and 
colleagues at the end of the 1990s.[24] Subsequently, this mecha-
nism was exploited for crosslinking entirely synthetic PEG 
hydrogels under physiological conditions.[25] In this approach, 
two PEG precursors, one with a glutamine-containing sequence 
and one with a lysine-containing sequence, served as substrates 
for factor XIIIa to be coupled.
In this work, we replaced PEG-Lys with gelatin, which 
natively contains lysine residues that can serve as a donor sub-
strate without any further modifications. We hypothesized that 
by using a material with inherent cell-responsive elements, a 
close mimic of the natural environment of cells could be cre-
ated. In fact, gelatin is a denatured form of collagen, the most 
abundant protein in the human body.
The crosslinking agent FXIIIa is an FDA approved drug for 
treating patients with a blood coagulation disorder (trade names 
are Cluvot, CSL Behring; NovoThirteen, Novo Nordisk). These 
drug formulations of the enzyme are designed for injection 
into the blood stream. When applied in the gelPEG system, any 
potentially remaining activity of FXIIIa could be inactivated by 
plasmin prior to use for implantation purposes.[26] Combined, 
this convincingly highlights the safety of FXIII for hydrogel 
crosslinking. While PEG is a synthetic polymer, which is on 
the market for medicinal products,[27] its conjugated derivatives 
containing peptides remain to be translated toward the clinics. 
Furthermore, the incorporated laminins are recombinant and 
xenogen-free.
3.2. Modular Approach to Integrate Nonmodified  
Proteins in Hydrogels
Hybrid hydrogels that integrate synthetic and biologic mate-
rials, such as ECM-derived materials, are a promising way 
for synthesizing next-generation hydrogels.[28] Therefore, the 
approach of immobilizing ECM-derived proteins in synthetic 
materials was undertaken by several groups.[29] Such systems 
present a merger of both, biological complexity in a physico-
chemically controllable matrix. These previous modules of PEG 
platforms could only accommodate incorporation of ECM 
molecules of interest after their chemical or biological modi-
fication. While being elegant, it can be a laborious approach 
to modify all proteins of interest.[30] Therefore, the here taken 
approach of immobilizing unmodified proteins for tissue speci-
ficity presents a simpler hydrogel-platform. Laminins were 
chosen in this study as model proteins to demonstrate reten-
tion of bioactivity after incorporation in gelPEG. Additionally, 
laminins represent the most abundant protein in Matrigel. The 
successful incorporation illustrates the flexibility of the plat-
form as tissue-specific isoforms can be used for tailoring the 
platform’s accommodation of various cell types.
3.3. Characteristics of gelPEG Hydrogels
Optimization of the hydrogel composition revealed the best 
ratio between gelatin and PEG to be between 2:1 and 4:1 to 
form most effective hydrogels with low swelling ratio and sol 
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fraction. Increasing the gelatin over PEG concentration still 
led to reasonable hydrogel formation, an increase of PEG 
immediately impaired hydrogel formation. This indicates that 
the availability of lysine residues is the limiting factor in the 
reaction.
For this study we chose a 4:1 ratio, for which a relatively 
higher gelatin to PEG concentration ratio was the most ideal. By 
doing so, less steric hindrance from PEG is expected, which, in 
contrast to gelatin, cannot be further broken down and replaced 
by secreted ECM from encapsulated cells. However, the ratio 
might be further fine-tuned toward a 1:1 Gln:Lys molar ratio, to 
match the degradation of the hydrogel with the speed of matrix 
deposition of a specific tissue type of interest. In fact, it was 
shown previously that degradation of hybrid hydrogels can be 
further slowed down by the addition of a synthetic polymer.[31] 
While for vasculogenic and osteogenic cocultures, gelPEG 
hydrogels roughly retained their initial volume over culture 
time, this was not the case for Matrigel-based cocultures. Also, 
Matrigel constructs of liver organoid cultures appeared very 
instable after a culture period of 9 d, which was less apparent 
in gelPEG hydrogels. For further fine-tuning toward upscaled, 
clinically relevant approaches for liver organoids, it might be 
therefore suggested to slightly increase either the total polymer 
or PEG-Gln concentration.
Matrigel has a low and highly variable elastic modulus, 
ranging from ≈0.4 to 3 kPa.[32] The 2% gelPEG hydrogels with a 
compressive modulus of 2.6 kPa ± 0.6 were the closest possible 
(low protein content) Matrigel mimics from a mechanical point 
of view that could be created. This comparable stiffness of the 
materials rules out its potential role as effector of the observed 
cell behavior.
3.4. Vasculogenesis in gelPEG Matrices
Clinically relevant-sized tissue analogues generally require a 
prevascular network before implantation. The presence of such 
an engineered capillary-like network throughout the construct 
can accelerate the connection with the patients’ own vascula-
ture, which is critical for implant survival.[33] Especially Matrigel 
is known for its proangiogenic properties that allow for the fast 
formation of a vascular-like network. Due to this reason it is an 
often used, highly potent material for vasculogenesis/angiogen-
esis-related assays.[11,34]
Prevascular network development over time by human 
ECFCs was initially favored in Matrigel compared to gelPEG. 
A thickening of capillary-like structures might indicate further 
maturation (i.e., arteriogenesis).[35] In this study, maturity of 
the networks was shown by the presence of stabilized capillary-
like structures and by the presence of lumen. The initial dif-
ference in performance between Matrigel and gelPEG might 
be explained by the proangiogenic properties of Matrigel, 
which are mediated by proteins such as collagen type IV 
and LN111[9,36] that might enable faster vasculogenesis. This 
assumption is supported by this work where addition of LN111 
to osteogenic cultures resulted in improved vascular structure 
formation. All in all, the gelPEG hydrogel performed equally 
well as the gold standard Matrigel in terms of long-term prevas-
cularization, both in extent and in maturity.
3.5. Engineering Prevascularized Bone-Like Tissue Analogues
Following, a bone-like construct was engineered as a model tissue, 
which requires simultaneous development of a prevascular 
network during bone forming. Early osteogenic differentiation 
on the protein level of all hydrogel constructs was shown by the 
presence of osteonectin. Comparable gene expression levels 
for osteopontin and osteocalcin indicated a comparable extent 
of osteogenic differentiation in all conditions. However, min-
eralization, a late phenomenon during osteogenesis, was only 
present in gelPEG-based hydrogels. While it is known from 
literature that osteogenesis is supported by Matrigel,[37] the 
presence of mineralization becomes generally prevalent after 21 d 
of culture.[38] Therefore, the absence of mineralization in MG 
after 14 d culture is in agreement with literature. Whereas nine 
out of nine gelPEG hydrogels were characterized by mineraliza-
tion after only 14 d, seven out of nine gelPEG+LN111 hydrogels 
were positive for von Kossa staining. Pure gelPEG hydrogels 
strongly supported early matrix mineralization, which can be 
explained by the gelatin extraction method. Gelatin is charac-
terized by nucleation sites. Especially, anionic gelatin (obtained 
by alkaline extraction) enables pronounced calcium binding 
of the matrix due to its negative charge at physiological pH.[39] 
Therefore, due to the nature of the gelatin in gelPEG hydro-
gels, the matrix is especially favorable as a template for bone 
development.
The addition of LN111 to gelPEG hydrogels led to an 
enhanced and more homogenous distribution of minerals 
throughout the matrix. At the same time, vasculogenesis was 
stimulated as indicated by a significantly longer vascular net-
work length. LN111 was shown to enhance vasculogenesis, 
which corresponds to literature.[9] The influence of LN111 on 
osteogenesis, especially on mineralization via inducing calcium 
phosphate precipitation, was established in previous studies.[40] 
Together, gelPEG hydrogels appeared as suitable templates 
for bone development, in which bioactives can enhance tissue 
development. Specifically, LN111 can be a potent stimulator of 
vasculogenesis in these constructs. Further fine-tuning of the 
LN111 concentration, all or not combined with additional fac-
tors, might help to optimize the balance between enhanced 
vasculogenesis and robust mineralization of all hydrogel 
constructs.
VE-cadherin is an endothelial cell–cell contact marker[41] 
and has a key role in endothelial barrier function and angio-
genesis.[42] While the highest VE-cadherin expression is 
apparent in Matrigel, it might be plausible that downregula-
tion of VE-cadherin in both gelPEG groups was a result of a 
more complete maturation status of the cells in the prevascular 
structures, supported by the apparent staining of CD31 and 
αSMA.
In contrast to purely vasculogenic cultures, vasculo-osteo-
genic cultures resulted in significantly lower vascular network 
length in pure gelPEG hydrogels compared to Matrigel. This 
difference can be explained by the added medium. For the 
osteogenic differentiation with simultaneous vasculogenesis, 
osteogenic medium was used instead of vasculogenic medium. 
Thus, in this condition, ECFCs obtain vasculogenic signals 
from the embedded MSCs[43] and not from the medium. There-
fore, when the vasculogenic stimulation is not induced by the 
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culture medium, adequate vascularization can be achieved by 
incorporation of LN111 in the hydrogel.
The novel gelPEG hydrogel platform allowed for the suc-
cessful engineering of prevascularized bone-like tissue ana-
logues. Due to the faster osteogenic differentiation while 
maintaining simultaneous vasculogenesis, gelPEG hydrogels 
even outperformed Matrigel for engineering of prevascularized 
bone-like constructs.
3.6. Engineering Liver-Like Tissue Analogues
GelPEG was tested with hepatic organoids[44] to evaluate the 
potential in comparison to the gold standard, Matrigel. Overall, 
the addition of LN111 or LN521 did not show a beneficial effect 
over pure gelPEG hydrogels, apart from albumin expression. 
However, compared to Matrigel, gelPEG with added laminins 
improved liver organoid differentiation as shown by elevated 
albumin expression and both ALAT and ASAT activity levels. 
This positive effect of LN521[22] and in a mix with LN111, 
was described previously where efficient hepatocyte differen-
tiation and self-organization occurred on laminin-coated sur-
faces on pluripotent stem cells.[22a] Especially with respect to 
metabolic function and self-organization of hepatocytes, LN 
coatings outperformed a Matrigel control. The minor nega-
tive effect of the addition of LN521 on hepatic enzymes and 
CYP-expression compared to gelPEG alone is in contrast with 
reports by others.[22] Since the addition of the LN521 in the 
pluripotent stem cells is already at the endodermal differentia-
tion stage, this indicates that the effect is not as profound on 
hepatic organoids which are considered a more mature stem 
cell type.[45]
Furthermore, hepatocyte metabolic activity was strongly 
affected in the different hydrogel compositions. From day 
1 until day 3 the cell activity doubled in Matrigel and gelPEG 
hydrogels, and increased 3.5 and 6 times in hydrogels laden 
with LN111 and LN521, respectively. This increase in meta-
bolic activity might correlate with cell proliferation. It has been 
shown that laminins are supporting survival and proliferation 
of multiple cell types. This strong increase in metabolic activity 
in gelPEG hydrogels compared to Matrigel in the beginning 
of the culture period might be due to enhanced proliferation, 
stimulated by the comparably stiff gelPEG hydrogels. It was 
shown by Gjorevski et al., that a higher matrix stiffness in PEG 
hydrogels was associated with intestinal stem cell proliferation, 
whereas softer hydrogels were needed for cell differentiation.[13a] 
The authors also demonstrated that matrix-metalloproteinase 
(MMP)-sensitive PEG hydrogels (with RDG-sites) could not be 
degraded fast enough by the cells to allow for organoid differ-
entiation after an initial proliferation phase. Consequently, they 
added a hydrolytically degradable polymer to the PEG platform 
to speed up the degradation process after an initial prolifera-
tion phase. In the present hydrogel system, combining gelatin 
and PEG, this cell-mediated degradation and remodeling of 
the matrix might occur naturally. After reaching a higher cell 
number during the initial proliferation phase, secreted MMPs 
might speed up the degradation process, resulting in a softer 
hydrogel, suitable for cell differentiation. This assumption can 
be supported by the fact that after the initial 3 d the metabolic 
activity gradually dropped in all hydrogel compositions, which 
might indicate a phase of cell differentiation.
Furthermore, it was shown recently that natural matrices 
were characterized by fast stress relaxation properties, a fea-
ture that synthetic hydrogels are typically missing and which 
appeared to be critical in guiding cell differentiation.[46] By 
using hybrid hydrogels as presented here, this natural charac-
teristic of the extracellular matrix might be present and could 
have contributed to the permission of multiple cell differentia-
tion into the vasculogenic, osteogenic, and hepatocyte lineages.
The use of gelPEG hydrogels was demonstrated here for the 
biological suitability as extracellular matrix of multiple tissue 
engineering approaches. In the future, gelPEG might also be 
used as a “bioink” for biofabrication processes due to its fast 
crosslinking.[47] In combination with reinforcing materials, 
such as offered by thermoplastics,[48] complex and multitissue 
type tissue analogues might be realized. Furthermore, these 
complex biofabricated tissue constructs might be character-
ized by a multiscale vascular tree consisting of engineered 
macrovessels and self-assembled capillary-like structures[21b] 
throughout the construct.
4. Conclusions
This research demonstrates that a simple hydrogel composed 
of gelatin and PEG can replace and even outperform Matrigel 
for complex, long-term tissue engineering approaches. With 
this, a clinically relevant, degradable biomaterial was developed, 
which can efficiently support cell differentiation and matrix 
secretion toward the development of functional tissue ana-
logues. Moreover, this novel gelPEG platform is easily tailorable 
with (combinations of) lysine-containing proteins to establish 
a tissue-specific matrix; illustrated here by addition of tissue-
specific laminins. Additional ECM-mimicking cues can prove 
valuable to create spatial resolution in a hydrogel when aiming 
at multiple tissue types within one biomaterial, sharing one 
culture medium.
The presented hybrid hydrogel can be readily applied to 
other tissue engineering approaches by fine-tuning the ratio 
between gelatin and PEG, the total polymer concentration, and 
by covalently immobilizing relevant proteins to further stimu-
late tissue development. Taken together, we suggest that such 
hybrid hydrogels consisting of PEG-Gln and a relevant biologic 
material, catalyzed by FXIIIa, will help to overcome the bioma-
terial-associated bottleneck of implementing complex tissue 
engineering in the clinics.
5. Experimental Section
Materials: Alkaline treated porcine skin gelatin (beMatrixTM LS-H 
high bloom, Nitta Gelatin NA Inc) with an endotoxin count less than 
10 endotoxin units (EU) g−1 was used. The gelatin was set to a pH of 
7.5, sterile filtered and freeze dried. The peptide was purchased from 
NeoMPS (Strasbourg, France). Eight-arm PEG-vinyl sulfone (8-PEG-
VS, mol wt 40 kDa) was obtained from NOF Europe (Grobbendonk, 
Belgium).
Synthesis of PEG-Gln Macromeres: PEG-Gln was synthesized and 
characterized as described previously.[25,49] In brief, a glutamine 
acceptor substrate (H-NQEQVSPL-ERCG-NH2, TG-Gln) was used. The 
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NQEQVSPL cassette corresponds to a substrate site of FXIII in an 
α2-plasmin inhibitor[24b] and the ERCG cassette contains a cysteine that 
can react with VS.[50] This TG-Gln substrate was coupled to 8-PEG-VS via 
Michael-type addition at a 1.2-fold molar excess of TG-Gln to PEG-VS 
in 0.3 m triethanolamine (pH 8.0) at 37 °C for 2 h. The reaction product 
was dialyzed, freeze dried, and PEG-Gln conjugation was confirmed by 
1 H NMR.
Formation of Gelatin-PEG Hydrogels: Factor XIII (200 U mL−1, Cluvot, 
CSL Behring) was activated with 20 U mL−1 thrombin (Baxter) in the 
presence of 2.5 × 10−3 m CaCl2 for 15 min at 37 °C and stored at −80 °C 
in small aliquots (FXIIIa). Hydrogel formulations consisting of different 
ratios of PEG-Gln and gelatin were formulated in tris-buffered saline 
(TBS, pH 7.6, 40 × 10−3 m) containing 50 × 10−3 m calcium chloride. 
Hydrogel crosslinking was initiated upon addition of 10 U mL−1 factor 
XIIIa. For biomaterial characterizations, disc-shaped hydrogels with 
8 mm diameter were prepared in a silicone sheet with 1 mm height 
(BioPlexus Corporation). The reaction mixture was left to crosslink for 
1 h in a humidified incubator when covalent crosslinks were formed 
between native lysines of gelatin or extracellular matrix-derived proteins 
and the Gln-conjugates on PEG (Figure 1).
Hydrogel Mass Loss and Swelling Analysis: GelPEG hydrogels were 
prepared in various lysine (Lys) and Gln molar ratios (Lys:Gln) 
ranging from 1:1 to 6:1 for a 3% w/v total polymer concentration and 
swelling analysis was performed. Furthermore, gelPEG hydrogels were 
prepared at a polymer concentration of 1 and 2% w/v at a ratio of 4:1. 
All hydrogels were characterized by means of swelling and mass loss 
studies, as described previously[51] for n = 5 technical replicates. In brief, 
immediately after crosslinking, the wet weight of the hydrogels was 
measured (minitial,t = 0). Per experimental group, 10 gels were prepared, 
from which five were directly frozen, lyophilized, and weighed (mdry, t = 0) 
and the other five were incubated in TBS for 24 h at 37 °C before the wet 
weight (mswollen) and the dry weight were determined (mdry, t = 1). The sol 
fraction describes the polymer concentration that is not crosslinked into 
the network and is therefore lost during hydrogel swelling. The hydrogel 
swelling ratio (q) and the sol fraction were calculated according to the 
following Equations (1–4)[52]
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Rheological Analysis of Hydrogel Formation: The crosslinking of 
gelPEG hydrogels at 2% w/v and 4:1 ratio by 10 U mL−1 FXIIIa was 
investigated (n = 3). An AR G-2 rheometer (TA-Instruments, the 
Netherlands) was used with the software TA Instruments Trios 
V4.3.0.38388. The testing was performed at 0.1% strain and 1 Hz 
continuous oscillation at 37 °C for 30 min under a humidified 
atmosphere. The point of gelation of the reactions was measured by 
recording the time when the shear storage modulus (G′) was equal 
to the shear loss modulus (G″) by analyzing tan δ = G″/G′. n = 3 
independent measurements were performed.
Mechanical Properties of Swollen Hydrogels: The elastic modulus of the 
hydrogels was determined after equilibration for 24 h in PBS at 37 °C. By 
means of a dynamic mechanical analyzer (DMA 2980, TA instruments) 
compression was applied between −20% per min and −30% at room 
temperature (RT). The elastic modulus was based on the slope from the 
linear region of the stress–strain curve of a strain range between 5% and 
10% (n = 5 technical replicates).
Coupling of Laminins into gelPEG Hydrogels: To investigate the 
coupling of lysine containing proteins into the gelPEG hydrogel network, 
laminin 521 (Biolamina, Sweden) served as a model protein. Laminin 
521 (LN) was added at a concentration of 10 µg mL−1 to the reaction 
mixture of 3% w/v 4:1 gelPEG in TBS (n = 5 technical replicates). 
Hydrogels without LN served as a control (n = 5 technical replicates). 
Hydrogel discs (≈1 × 5 mm) of 20 µL volume were incubated for 24 h 
at 37 °C in TBS. All hydrogels were washed and fixed in 4% formalin 
and stained with a primary anti-LN α5 antibody (1:260, clone 4C7, 
MAB1924, Merck), followed by a goat-antimouse antibody Alexa Fluor 
546 (4 µg mL−1, A-11 003, Thermofisher). Imaging of control and 
LN-laden hydrogels occurred with a fluorescence microscope 
(BX51, Olympus).
Cell Isolation, Culture, and Characterization: Multipotent mesenchymal 
stromal cells (MSCs) were derived from human bone marrow aspirates 
from the iliac crest of three patients after ethical approval and informed 
consent (University Medical Center Utrecht, 08-001-K). The white 
mononuclear cell (MNC) fraction was separated via density gradient 
centrifugation on Ficoll-paque PLUS (1.077 g mL−1, GE healthcare). 
The collected cells were expanded in expansion medium composed 
of α-MEM (Gibco), 10% v/v heat-inactivated fetal bovine serum (FBS, 
Lonza), 100 U mL−1 penicillin, 10 mg mL−1 streptomycin (Gibco), 
0.2 × 10−3 m l-ascorbic acid-2-phosphate (ASAP, Sigma) and 
1 ng mL−1 basic fibroblast growth factor (bFGF, 233-FB R&D Systems), 
at 37 °C/ 5.0% CO2. MSCs were identified by their capacity to undergo 
differentiation toward the osteo-, adipo-, and chondrogenic lineages. 
Furthermore, fluorescence-activated cell sorting (FACS) characterization 
of the MSCs was performed showing absence of the hematopoietic 
markers CD14 (RPA-M1, fluorescein isothiocyanate (FITC)-conjugated, 
Abcam), CD34 (4H11, AP-conjugated, Abcam), CD45 (MEM-28, 
PE-conjugated, Abcam), and CD79a (HM47, PE-conjugated, Abcam) 
and presence of the established MSC-like markers CD90 (5E10, FITC-
conjugated, Abcam), CD105 (MEM-226, AP-conjugated, Abcam), and 
CD73 (AD2, PE-conjugated, Abcam). Cells were used up to passage 4.
Human endothelial colony forming cells (ECFCs) were derived from 
three human umbilical cord blood donors after caesarean sections 
according to the local ethical guidelines (University Medical Center 
Utrecht, METC 01–230/K). The obtained cord blood was diluted 1:1 with 
PBS 2 × 10−3 m EDTA before density gradient centrifugation on Ficoll-
paque. The harvested cells were cultured on rat collagen type I (Corning) at 
a seeding density of 10–20 × 106 cells cm−². Endothelial growth medium-2 
(EGM-2) was composed of endothelial basal medium-2 (EBM, Lonza), 
10% v/v FBS, 100 U mL−1 penicillin, 10 mg mL−1 streptomycin and EGM-2 
singlequots (Lonza). During the first 7 d after isolation, the medium was 
refreshed daily. Colonies with cobblestone-like morphology were picked 
after 14–21 d and were further expanded. ECFCs were characterized by 
FACS where they were positive for CD105 and CD31 (TLD-3A12, FITC-
conjugated, Abcam), partially positive for CD34 and CD309 (VEGFR/KDR, 
PE-conjugated, MACS Miltenyi Biotech) and negative for CD45, CD14, 
and CD133 (AC133-VioBright, FITC-conjugated, Miltenyi Biotech). ECFCs 
were used up to passage 10. Furthermore, ECFCs were transduced with 
green fluorescent protein (GFP) in a pHAGE-2 vector with a human EF-1α 
promotor as described previously.[21b]
Human liver organoid cultures were generated from three donors 
from surplus material of donor livers used for liver transplantations 
performed at the Erasmus Medical Centre Rotterdam (courtesy of 
Dr. Luc van der Laan, approved by the Medical Ethical Council of the 
Erasmus MC).[45]
The organoids were grown in Matrigel in Expansion Medium (EM), 
as previously described by Huch et al.[45] A total of 7 to 5 d prior to 
differentiation toward hepatocyte-like cells the EM was supplemented 
with 25 ng mL−1 BMP-7 (Peprotech, London, UK). At day 0, the 
organoids were passaged with a split rate of 1:1 and reseeded in 
3% w/v 4:1 gelPEG or Matrigel (Corning, 354 230, Growth Factor Reduced 
Basement Membrane Matrix). Differentiation medium (DM) containing 
advanced DMEM/F12 (Gibco, Dublin, Ireland) supplemented with 
1% v/v Penicillin-Streptomycin (Thermo Fisher Scientific, Waltham, MA, 
USA), 1% v/v N2, 1% v/v B27, 10 × 10−3 m HEPES, 1% v/v Glutamax, 
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50 ng mL−1 EGF (all from Invitrogen, Carlsbad, CA, USA), 1.25 × 10−3 m 
N-acetyl cysteine (Sigma-Aldrich, St Louis, MO, USA), 5 × 10−6 m A83-01 
(Tocris Bioscience, Bristol, UK), 25 ng mL−1 HGF, 10 × 10−9 m Gastrin, 
25 ng mL−1 BMP7 (all from Peprotech), 10 × 10−6 m DAPT (γ-secretase 
inhibitor, Selleckchem, Houston, TX, USA), 100 ng mL−1 FGF19 (R&D 
Systems, Minneapolis, MN, USA), and 30 × 10−6 m dexamethasone 
(Sigma-Aldrich) was added freshly every other day until the samples 
were collected (day 9).
MSC-ECFC Coculture in Hydrogels: MSCs and ECFCs were 
coencapsulated in gelPEG (2% w/v 1:4) hydrogels or Matrigel (Corning, 
354 230, Growth Factor Reduced Basement Membrane Matrix) reaching 
a final seeding density of 5 × 106 MSCs and 1.25 × 106 ECFCs per mL gel. 
Besides CaCl2, TBS, and FXIIIa, the reaction mixture contained 20% of cell 
culture medium. Furthermore, cocultures were encapsulated in Matrigel 
which was 1:1 diluted with TBS including 20% of cell culture medium.
For vasculogenic cultures, GFP-labeled ECFCs were used. For 
each condition, three hydrogel droplets of 75 µL each were placed in 
the center of wells in a 12-well plate. To track formation of capillary-
like structures over culture time, hydrogels were imaged on days 
2 and 6 using an inverted fluorescence microscope (IX53 Inverted 
Fluorescence Microscope, Olympus). Hydrogels were cultured in EGM-2 
for 10 d, fixed in formalin, and cut in three pieces for different stainings. 
MSCs from three different donors were combined with GFP-ECFCs from 
one donor (N = 3 different donors, n = 3 technical replicates).
To induce osteogenesis and simultaneous vasculogenesis, hydrogels 
were prepared as for vasculogenic cultures. MSC-ECFC cocultures 
in gelPEG and gelPEG combined with 10 µg mL−1 laminin 111 were 
compared to cultures in Matrigel. The cocultures were cultured in 
osteogenic differentiation medium (ODM) for 2 weeks. ODM was 
composed of α-MEM, 10% FBS, 100 U mL−1 penicillin, 10 mg mL−1 
streptomycin, 10 × 10−3 m β-Glycerolphosphate (Sigma), and 10 × 10−9 m 
dexamethasone (Sigma). Six hydrogels per condition were prepared, of 
which three were used for qPCR analysis and three were fixed, cut and 
used for paraffin embedding and whole mount fluorescent stainings. All 
experiments were performed with three MSC-ECFC combinations from 
different donors (N = 3, n = 3).
Liver Organoid Culture in Hydrogels: Liver organoids from three 
different donors were encapsulated in Growth factor reduced Matrigel 
(456 231, Corning, New York, NY, USA), 3% w/v 1:4 gelPEG, gelPEG 
with 10 µg mL−1 LN111, or gelPEG with 10 µg mL−1 LN521. The gelPEG-
cell mixture contained 20% medium, whereas Matrigel was used 
undiluted. Hydrogel droplets with a volume of 40 µL were placed in the 
center of culture wells and DM media was added. On days 1, 3, 6, and 
9 of differentiation the viability of the organoids was measured with an 
Alamar Blue assay according to the manufacturer’s guide (Invitrogen). 
A total of 9 days after differentiation samples were collected for gene-
expression profiling and enzyme measurements. For gene-expression 
profiling, organoids were lysed with 350 µL RLT (Qiagen, Hilden, 
Germany) and stored at −20 °C until further analysis. For enzyme 
measurements, organoids were lysed in Milli-Q water (Merck Millipore) 
at −20 °C until analysis. ALAT, ASAT, LDH, GLDH, albumin, and total 
protein were measured using the AU680 Beckman (Beckman Coulter, 
Brea, CA, USA) standard protocols, and values were corrected for total 
protein levels (N = 3, n = 3).
mRNA Isolation, cDNA Synthesis, and qPCR Analysis: After culture, 
cell-containing hydrogels were digested using 2 mg mL−1 collagenase 
A (Roche) for 10 min at 37 °C. The MSC-ECFC-containing pellet was 
then homogenized in TRIzol reagent (Thermo Fisher Scientific) and 
messenger RNA (mRNA) was isolated from the aqueous phase. 
Potential DNA contamination was removed by a DNAse treatment 
(Turbo DNAse; Thermo Fisher) according to the manufacturer’s 
instructions. The organoids were lysed with 350 µL RLT (Qiagen, Hilden, 
Germany) complemented with 1% v/v 2-Mercaptoethanol (Sigma-
Aldrich), and mRNA was isolated using the RNeasy micro-kit (Qiagen), 
following the manufacturer’s guide. The total extracted amount of 
mRNA was quantified with a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific) at 260/280 nm. Complementary DNA (cDNA) 
was synthesized from 1 µg mRNA using the iScript cDNA Synthesis Kit 
(Bio-Rad, Hercules, USA) according to the manufacturer’s instructions. 
qPCR analysis was executed with a Bio-Rad CFX96 Real-Time PCR 
Detection System (Bio-Rad) using FastStart SYBR Green Master mix 
(Sigma-Aldrich) and an input of 20 ng cDNA per reaction. Primers used 
for qPCR analysis are listed in Table S1 (Supporting Information). The 
amplification efficiency of the used primers was all between 0.9 and 1.1 
and the relative expression was determined by the 2−ΔCT formula.
For liver organoid cultures, the same protocol was followed using 
a Bio-Rad CFX384 Real-Time Detection System and an input of 10 ng 
cDNA per reaction. A housekeeping index was calculated based on a 
previously published formula based on GAPDH and YWHAZ.[53]
Whole Mount Fluorescent Stainings: Prior to immunofluorescent 
stainings, the hydrogel constructs were permeabilized with 0.2% triton-X 
in PBS for 30 min and blocked in 5% BSA/PBS for 30 min. Capillary-
like structures in the hydrogels were investigated by CD31 staining 
(5.1 µg mL−1, M0823, Dako), secondary sheep antimouse biotinylated 
antibody (1:200, RPN1001v1, GE Healthcare), and tertiary streptavidin 
Alexa Fluor 488 conjugate (5.0 µg mL−1, S32354, Invitrogen). In 
vasculogenic cocultures, ECFCs with the GFP label were not stained for 
CD31. The endothelial phenotype was confirmed by a rabbit antivascular 
endothelial cadherin antibody (VE-cad, 1:250, D87F2, Cell Signalling 
Technology) which was combined with a secondary donkey-antirabbit 
Alexa 647 antibody (5 µg mL−1, ab150075, Abcam). Stabilizing cells of 
the capillary-like structures were identified by a mouse monoclonal Cy3-
conjugated αSMA antibody (1:300 µg mL−1, Clone 1A4, C6198 Sigma 
Aldrich). Furthermore, 4,6-diamidino-2-phenylindole (DAPI, 100 ng mL−1, 
Sigma) was used to stain cell nuclei. The hydrogels were imaged with a 
confocal microscope (SP8x Leica, DMi8, Leica).
Immunohistochemistry: Fixed osteogenically differentiated hydrogels 
were dehydrated in graded ethanol series. After clearance in xylene, 
the hydrogels were embedded in paraffin and sectioned into 5 µm 
slices. An osteonectin staining was performed after deparaffinization 
and rehydration before endogenous peroxidase was blocked in 0.3% 
H2O2. Citrate buffer (pH 6) was used for antigen retrieval at 80 °C for 
20 min. The primary antibody for osteonectin (4.2 µg mL−1, AON-1, 
deposited to the DSHB by Termine, J.D.; DSHB (Developmental 
Studies Hybridoma Bank, created by the NICHD of the NIH and 
maintained at The University of Iowa, Department of Biology, Iowa 
City, IA 52242) Hybridoma Product AON-1[54]) was incubated for 1 h, 
followed by a horseradish peroxidase–conjugated antimouse antibody 
(Envision + system-HRP labeled polymer, K4000 Dako). Detection of 
osteonectin occurred by conversion of 3,3’-diaminobenzidine solution 
(SK-4100, Vector) with counterstain for nuclei by hematoxylin (Merck). 
Concentration-matched isotype controls were performed using a mouse 
IgG1 monoclonal antibody (Thermofisher Scientific).
A von Kossa staining was performed to detect mineralization of the 
osteogenically differentiated cocultures. After deparaffinization and 
rehydration, the samples were incubated with 1% silver nitrate solution 
(Fisher Scientific) under a light bulb for 1 h. Unreacted silver was 
removed by rinsing with 5% sodium thiosulfate (Alfa Aesar GmbH) for 
5 min. Nuclear counterstaining was performed with hematoxylin.
The organoid-containing hydrogels were digested using 2 mg mL−1 
collagenase A (Roche) for 10 min at 37 °C. The organoids were fixed 
in 10% neutral buffered formalin, embedded in paraffin, and sections 
of 4 µm were cut. H&E staining (Merck KGaA, Darmstadt, Germany) 
was routinely performed. Imaging was performed using an Olympus 
microscope (CKX41) in combination with a Leica DFC425C camera.
Image Analysis: Hydrogels of vasculogenically differentiated cultures 
(GFP-ECFCs) were imaged at the thickest part of the hydrogel (center) 
on a confocal microscope (SP8x Leica, DMi8). Projections of 150 µm 
z-stacks were made (one stack per hydrogel, n = 9 stacks per condition), 
which were adapted in contrast and intensity with ImageJ 1.51a before 
batch-processing of the images. Angioquant software[55] was used to 
analyse the vascular networks’ total vessel length as well as average 
thickness of vessels by dividing the total vessel area by the total 
vessel length. For osteogenic cocultures, 100 µm z-stacks were made, 
processed in ImageJ and the total vessel length was quantified with 
Angioquant (n = 9 projections per condition).
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Statistics: For mass loss studies, a one-way ANOVA was performed 
with a Tukey HSD post hoc analysis using Graphpad prism 7.02. For 
the compressive moduli, significance was determined by a Student’s t-
test in Graphpad prism 7.02. For osteogenic and hepatic cell cultures, 
MS Excel 2010 (Microsoft, Redmond, USA) was used for calculations 
and PASW Statistics 22.0 (SPSS Inc. Chicago, USA) for statistical 
analysis. To take into account donor variations, a mixed linear model 
(after log-transformation for osteogenically differentiated constructs) 
was conducted followed by a Bonferroni’s post hoc test to compare 
gene expressions between the tested hydrogel types. In the model, the 
hydrogel type was considered as a fixed factor, while the cell donors 
were considered as random factors (n = 3 gels per group). Differences 
were considered statistically significant for p < 0.05 and the Bonferroni 
corrected p-values are depicted in the figures. Asterisks represent 
statistical significances according to p values (*p < 0.05; **p < 0.01; 
***p < 0.001), N refers to the number of independent experiments (with 
different cell donors), and n refers to the technical replicates.
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